环丝氨酸与利奈唑胺治疗结核性脑膜炎:药代动力学证据提示潜在有效性
在格鲁吉亚第比利斯开展的一项临床药理学研究纳入17例结核性脑膜炎患者,交替于2小时和6小时采集脑脊液与血清。环丝氨酸和利奈唑胺脑脊液穿透率为中至高度,贝达喹啉、氯法齐明和德拉马尼的脑脊液浓度均低于检测下限。
要点
- 环丝氨酸2小时和6小时脑脊液中位浓度分别为15.90和15.10 µg/mL,校正脑脊液/血清比值为0.52和0.66。
- 利奈唑胺2小时和6小时脑脊液浓度分别为0.90和3.14 µg/mL,校正比值为0.25和0.59。
- 贝达喹啉、氯法齐明和德拉马尼所有脑脊液测定值均低于检测下限。
核心结论
- 基于中至高度的脑脊液穿透率,利奈唑胺和环丝氨酸可能是治疗结核性脑膜炎的有效药物,而贝达喹啉、德拉马尼和氯法齐明的效用因脑脊液穿透率低而不确定。
研究设计与样本
- 在格鲁吉亚第比利斯开展的一项临床药理学研究,纳入2019年1月至2020年1月期间接受治疗的结核性脑膜炎患者。
- 共纳入17例接受结核性脑膜炎治疗的患者(8例为确诊结核性脑膜炎),所有患者均接受利奈唑胺治疗,部分患者接受环丝氨酸(5例)、氯法齐明(5例)、德拉马尼(4例)和贝达喹啉(2例)治疗。
- 住院期间采集系列血清和脑脊液样本,脑脊液通过常规腰椎穿刺采集,穿刺时间交替安排在2小时和6小时以捕捉早期和晚期脑脊液穿透。
主要发现
- 环丝氨酸2小时和6小时脑脊液中位浓度分别为15.90和15.10 µg/mL,校正脑脊液/血清比值分别为0.52和0.66。
- 利奈唑胺2小时和6小时脑脊液浓度分别为0.90和3.14 µg/mL,校正脑脊液/血清比值分别为0.25和0.59。
- 利奈唑胺脑脊液浓度不受利福平联用影响。
- 贝达喹啉(12次测定)、氯法齐明(24次测定)和德拉马尼(19次测定)的所有脑脊液测定值均低于检测下限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The ability of antituberculosis drugs to cross the blood-brain barrier and reach the central nervous system is critical to their effectiveness in treating tuberculosis meningitis (TBM). We sought to fill a critical knowledge gap by providing data on the ability of new and repurposed antituberculosis drugs to penetrate into the cerebrospinal fluid (CSF). METHODS: We conducted a clinical pharmacology study among patients treated for TBM in Tbilisi, Georgia, from January 2019 until January 2020. Serial serum and CSF samples were collected while patients were hospitalized. CSF was collected from routine lumbar punctures with the timing of the lumbar puncture alternating between 2 and 6 hours to capture early and late CSF penetration. RESULTS: A total of 17 patients treated for TBM (8 with confirmed disease) were included; all received linezolid, with a subset receiving cycloserine (5), clofazimine (5), delamanid (4), and bedaquiline (2). All CSF measurements of bedaquiline (12), clofazimine (24), and delamanid (19) were below the limit of detection. The median CSF concentrations of cycloserine at 2 and 6 hours were 15.90 and 15.10 µg/mL with adjusted CSF/serum ratios of 0.52 and 0.66. CSF concentrations of linezolid were 0.90 and 3.14 µg/mL at 2 and 6 hours, with adjusted CSF/serum ratios of 0.25 and 0.59, respectively. CSF serum linezolid concentrations were not affected by rifampin coadministration. CONCLUSIONS: Based on moderate to high CSF penetration, linezolid and cycloserine may be effective drugs for TBM treatment, whereas the utility of bedaquiline, delamanid, and clofazimine is uncertain given their low CSF penetration.
引用
- Kempker RR, Smith AGC, Avaliani T, et al. Cycloserine and Linezolid for Tuberculosis Meningitis: Pharmacokinetic Evidence of Potential Usefulness. Clin Infect Dis. 2022. PMID: 34849645. doi:10.1093/cid/ciab992
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。